Boryung Biopharma changed from selling al... > 경제기사 | economics

보령바이오파마 진천공장 전경 사진=보령

[Alpha Biz=Chicago Reporter Paul Lee] Boryeong BioPharma, which made its third sale after two failed sales, turned from the full sale to the sale of its 90% stake.

According to the investment banking IB industry on the 12th, the sale of Boryeong Biopharma, a subsidiary of Boryeong Group, has been reduced to 90% from the entire stake. Boryeong Partners 69.29% stake, the largest shareholder, decided to sell only 59.29%, leaving a 10% stake. Boryeong Partners decided to remain the second largest shareholder, expecting the company to grow further even after the sale. It is also known that the calculation is based on the impression that the owner is a company that he or she will rely on to complete the sale.

The shareholders of Boryeong Biopharma are Boryeong Partners 69.29% stake, Boryeong Partners CEO and Boryeong Group third-generation manager Kim Jung-kyun 1.78%, and the owners family and financial investors FI. FI includes Shinhan BioPharma 8.77% and Mirae Asset Securities 3.69%.

The stake will be acquired by KL amp; Partners. Currently, we have signed a memorandum of understanding MOU and are receiving consent from existing financial investors FI. We formed a consortium for the acquisition. In addition to PCL, a company specializing in in vitro diagnosis, it is raising funds in partnership with the Pharmaceutical Bio Strategic Investor SI Corps. The acquisition is estimated to be worth a total of 450 billion won, including 50 billion won in cash held by the company.

관련기사

▶ Samsung Electronics established Business Development Group

▶ Hanmi Global has been newly appointed as a representative of three affiliates ... promoted to eight executive directors

▶ 삼성증권 PB, 고객돈 수십억원 빼돌려…경찰 수사, 뒤늦게 드러나

▶ 한국투자증권, 연금자산 적립금 15조원 돌파

▶ [심층] AJ네트웍스, 로봇렌탈 사업 본격 확대

/ 알파경제 폴 리 특파원